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Would you work with a gene, vector or oligonucleotide of unknown se-
quence? Today, the majority of scientists would answer with a resound-
ing ‘No’. Biology is becoming more quantitative, digital and deﬁned.
The availability of genomic sequences in public databases allows the
same genes to be effectively and reproducibly synthesized and studied
in different laboratories everywhere: where a sequence is available
there is no uncertainty. The genes, vectors, RNAs or oligonucleotides
I order will be indistinguishable from the ones you describe in your ex-
periments. This allows me to attempt to reproduce your experiments,
and while there may be differences in the protocols we use, at least we
can be sure that the underlying biological materials are essentially iden-
tical. However, the situation is very different when it comes to the spe-
ciﬁc detection of molecules in biological samples using ‘speciﬁc’ probes.
The most widely used speciﬁc binding reagents are synthetic nucleic
acid probes based on sequence knowledge. These are able to recognize
RNA or DNA by hybridization with enormous speciﬁcity and afﬁnity,
and rely on well-understood base complementarity for their high speci-
ﬁcity. For that reason, they are reproducible between laboratories, and
even partial cross-reactivities are predictable to some degree.
Nowadays, the sequences of oligonucleotides used in an experimental
study are typically listed in a Supplementary Table in each publication,
allowing relatively straightforward experimental duplication.
For historical, as well as practical, reasons, antibodies are by far
the most widely used class of speciﬁc detection reagents for essentially
all other target classes, particularly proteins. Polyclonal antisera have
been used in research for nearly a century, and monoclonal antibodies
for four decades (Köhler and Milstein, 1975). However, although
these reagents have been instrumental in addressing numerous bio-
medical research questions, they are never deﬁned at the molecular
level (we do not consider here the use of antibodies as biological phar-
maceuticals, as these are all highly quality-controlled, recombinant
reagents that have been exquisitely characterized). Animal-derived
reagent antibodies are the main subject of this editorial.
Without access to alternatives, researchers have become accus-
tomed to—and usually do not question—the inadequate deﬁnition
and characterization of these traditional reagents, even in an era
when working with oligonucleotides, genes, vectors or even genomes
of unknown sequence is inconceivable. Modern biomedical and clin-
ical research relies on speciﬁc, high-afﬁnity detection reagents that are
functional in complex environments. They provide information on
whether a particular component is present in a biological sample,
how much of it there is, where it is found, and with which other
macromolecules it interacts. The nature of the speciﬁc detection re-
agent in molecular terms (i.e. whether it is an antibody, another scaf-
fold or an aptamer) is less important than its quality, assessed in terms
of speciﬁcity, epitope recognized, afﬁnity and functionality in different
assays, and the ability to describe it sufﬁciently well that other scien-
tists can reproducibly use the same reagent.
Progress in research relies on reproducibility—the generation of
reliable results upon which future studies can be dependably based.
However, many experts, including NIH Director, Francis Collins, be-
lieve our ‘system for ensuring reproducibility of biomedical research is
failing’ (Collins and Tabak, 2014). Clearly, the ability to repeat ex-
periments with reagents identical to those used in previous publica-
tions is an essential part of creating a successful and reproducible
biomedical research environment.
For all those reagents deﬁned at the molecular or sequence level de-
scribed above, this is an achievable goal, and can be eliminated as a
source of irreproducibility. However, when it comes to antibodies,
the situation is very different for a number of different reasons.
Obviously, the molecular deﬁnition of polyclonal antibodies will re-
main impossible at a practical level, andwhile the genes of monoclonal
antibodies can be sequenced and therefore completely deﬁned, this is
rarely carried out.
In addition to the problem of inadequate deﬁnition, the situation is
further clouded by the fact that it is projected nomore than 35–50%of
commercial antibodies actually recognize their targets with the
claimed speciﬁcity (Berglund et al., 2008; Slaastad et al., 2011);
although this projection is unevenly distributed, with some manufac-
turers producing consistently high, and others consistently low, qual-
ity antibodies (Berglund et al., 2008; Bordeaux et al., 2010). This is
further exacerbated by intrinsic lot-to-lot variability, particularly
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with polyclonal antibodies, and two widely unrecognized market
practices: data sheets often do not even correspond to the lot sold
(Voskuil, 2014), and the same original antibodies are often sold by dif-
ferent providers under different labels (Alm et al., 2014; Voskuil,
2014). The problem is probably best summarized thus: antibodies
sold as different are often identical, while antibodies sold as identical
are often different (thanks to Natalie de Souza (editor NatureMethods)
for this pithy insightful observation), and the customer does not know
which is which.
Although most researchers consider monoclonal antibodies to be
perfectly deﬁned reagents with single speciﬁcities and so free of
these problems, hybridomas frequently secrete more than one light
and/or heavy chain (Ruberti et al., 1994; Zack et al., 1995; Blatt
et al., 1998). This makes it difﬁcult to assess whether the binding prop-
erties of a monoclonal antibody preparation are intrinsic to the mono-
clonal antibody molecule itself, or the result of additional speciﬁcities
caused by the presence of additional chains. This can only be deter-
mined when all expressed V genes are cloned and assessed for their
binding properties in all possible combinations. Furthermore, hybri-
domas are known to lose expression, or mutate, requiring frequent re-
cloning and testing. Given these caveats, the identity, reproducibility
(and monoclonality) of two purportedly identical monoclonal anti-
body samples derived from hybridomas cannot be clearly established.
Part of the problem is that protein–protein interactions are not near-
ly as predictable as base-pairing interactions in nucleic acids, making
the experimental conﬁrmation of antibody speciﬁcity prior to use essen-
tial (Bordeaux et al., 2010; Bourbeillon et al., 2010). However, even
when antibodies do recognize their targets speciﬁcally, there are add-
itional complexities. Antibodies are described in terms of the targets
they (should) recognize, rather than in terms of their identity: deﬁnition
of a reagent by what it does, rather than what it is, continues to be one
of the major problems in the antibody ﬁeld. Unfortunately, the ﬁrst def-
inition is not usually given with enough accuracy, and the second not at
all. Antibodies speciﬁcally recognizing the same target protein may rec-
ognize different epitopes (linear or conformational), or different iso-
forms, of that the same target. The epitopes recognized by antibodies
raised against peptides may be known, but are often not disclosed for
commercial reasons. Thus, users normally have no way of knowing
whether antibodies and/or their recognition speciﬁcities are identical,
and this can lead to different results in matching experimental set-ups,
even for antibodies that are truly speciﬁc for their targets.
This problem can only be overcome if antibodies, once character-
ized, become uniquely identiﬁable and their identities veriﬁable. As se-
quence is the deﬁning characteristic of modern biology, we propose
that the time has come to apply the gene-based paradigm to anti-
bodies. The sequence is, after all, a unique bar code.
In the short term, in order to raise the quality of antibodies used in
biomedical research (to reiterate, we are excluding therapeutic anti-
bodies, which are excellent), it will be indispensable to develop widely
adopted standards and best practices for antibody characterization
and validation. However, this is necessary but not sufﬁcient: in the
long term, biological research should plan for the introduction of
sequenced recombinant antibodies (or other binding molecules) as
research reagents. Sequences should be made publicly available so
that researchers can all use identical reproducible reagents (Bradbury
and Plückthun, 2015a,b). Such reagents will, of course, require the
same diligent characterization and validation as traditional antibodies—
knowledge of the sequence is clearly independent of and additional to
this requirement. However, unlike animal-derived antibodies, where this
should be carried out prior to each use, extensive characterization of re-
combinant sequenced antibodies will be required only once (Bradbury
and Plückthun, 2015a,b). Once binding and the concentration of active
molecules is conﬁrmed (using appropriate positive controls), it can
be safely assumed that antibody binding properties will be essentially
identical, providing they are produced under uniform conditions (it
should be noted that recombinant antibodies expressed in different
hosts can have different post-translational modiﬁcations. This can affect
the homogeneity of populations of recombinant antibodies of the same
sequence and contribute to differences in activity, hence the need for
uniformity in production and standard operating procedures).
Even though antibodies are widely considered to be an important
contributor to the irreproducibility problem plaguing biomedical
research (Begley and Ellis, 2012; Begley, 2013; Bradbury and
Plückthun, 2015a,b), it may be challenging to convince scientists to
switch from the animal-derived antibodies they are familiar with to re-
combinant sequenced binders, even if this does improve reproducibility
between different scientiﬁc studies. This indicates the need for collabor-
ation between funding agencies and journals. Just as it is now impossible
to publish the structure of a protein without depositing the coordinates
in the PDB, so it should become impossible in the future to describe the
use of an antibody that has not been deﬁned at the sequence level—
simply so that others can repeat the exact same experiment.
Commercial antibody providers are reluctant to release the se-
quences of the monoclonal antibodies they derive (Polakiewicz,
2015), regarding them (not unreasonably) as valuable proprietary
information. This indicates the likely need for funding from public
(or public–private partnerships) to derive and characterize antibodies
initially. In the short term, we anticipate that valuable monoclonal
antibody speciﬁcities should be cloned, sequenced and produced re-
combinantly, so avoiding the problems described above. In the longer
term, we would expect recombinant reagents to be produced directly
using display technologies. While antibodies have been widely used
for decades, there aremany new classes of afﬁnity reagents on the hori-
zon. These include recombinant antibodies created using natural or
synthetic sources (Bradbury et al., 2011), other recombinant protein
scaffolds (e.g. DARPINs, anticalins, afﬁbodies, ﬁbronectin domains)
(Binz et al., 2005; Skerra, 2007, Veesler et al., 2009), in which binding
is mediated by diversity introduced on one surface that interacts with
targets of interest; and nucleic acid-based afﬁnity reagents (aptamers
and SOMAmers), in which globular binding structures are provided
by intricate three-dimensional folding motifs unlike natural nucleic
acid folds (Davies et al., 2012).
Using sequence to deﬁne these different recombinant reagents will
allow them to compete in the research market place. Automation and
molecular engineering, including streamlining of characterization, is
just beginning, and expected to lead to signiﬁcant cost reductions.
Companies would then presumably compete on the quality, quantity
or price of the binding reagents they produce, based on their publicly
known sequences. The virtuous circle created by the need to disclose
speciﬁc binder sequences will ensure that the poorly characterized
irreproducible antibody will become a thing of the past.
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